Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BVS vs MXCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BVS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

BVS Overall Winner 6-Pillar Tally: BVS 5 – 1 MXCT Matrix Metrics: BVS 8 – 2 MXCT

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BVS carries a Unified Composite Score of 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin).

  • Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. MXCT 41.7/100 SELL) and 0.85β · 74% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BVS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BVS vs MXCT
BVS NASDAQ Head-to-Head Winner
Bioventus Inc. Class A Common Stock
Surgical & Medical Instruments & Apparatus
$9.88
-0.7% 1D
Market Cap $681.3M
TTM Revenue $586M
Forward P/E 11.1x
Beta / 30D Vol 0.85β · 74% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 64.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.4%), weak momentum, RSI 29
RSI-14: 28.8 · SMA20: $11.75 · SMA50: $12.81
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25

6-Pillar Scorecard Institutional Category Breakdown (BVS 5 – 1 MXCT)

Columns: Metric · BVS · MXCT
1. Valuation Multiples BVS
Forward P/E 11.1x N/M
Trailing P/E 12.3x N/M
PEG Ratio 1.20x N/M
EV / Revenue 1.5x 3.9x
2. Growth & Scale BVS
Revenue Growth (YoY) +2.7% +48.7%
Earnings Growth (YoY) +69.7% +0.0%
TTM Revenue (USD) $586M $34M
Market Cap $681.3M $132.2M
3. Profitability & Quality BVS
Gross Margin 68.7% 81.0%
Operating Margin 10.1% -85.5%
Net Profit Margin 9.8% -81.4%
Return on Equity (ROE) 25.8% -16.9%
4. Balance Sheet & Cash Flow BVS
Cash Generation (TTM) $85M -$24M
Cash Flow Margin 14.5% -69.2%
Net Cash / Leverage $199M Net Debt (0.96x D/E) $2.2M Net Debt (0.11x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MXCT
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 448.1% (100th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat BVS
OpEx & R&D Intensity 58.6% of Rev ($343M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BVS (8) vs MXCT (2)
Institutional Metric BVS MXCT Criterion Row Edge
Market Capitalization
Scale
$681.3M $132.2M Larger Scale BVS
Trailing P/E Ratio
Valuation
12.3x N/M Lower Multiple BVS
Forward P/E Ratio
Valuation
11.1x N/M Lower Multiple BVS
Revenue Growth (YoY)
Growth
+2.7% +48.7% Higher Growth MXCT
Operating Margin (TTM)
Profitability
10.1% -85.5% Higher Margin BVS
Net Profit Margin
Profitability
9.8% -81.4% Higher Margin BVS
Return on Equity (ROE)
Capital Efficiency
25.8% -16.9% Higher ROE BVS
52-Week Range Position
Momentum
36% ($6–$16) 63% ($1–$2) Stronger Trend MXCT
Beta / 30D Volatility
Risk Regime
0.85β · 74% Vol 1.19β · 96% Vol Lower Realized Risk BVS
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite BVS
Trailing 12M Revenue (USD)
Operating Scale
$586M $34M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.7% 81.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.20x PEG · 1.5x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$85M ($199M Net Debt (0.96x D/E)) -$24M ($2.2M Net Debt (0.11x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MXCT +30.11 pp
BVS: -34.31% · MXCT: -4.2%
3M Horizon MXCT +28.09 pp
BVS: -29.53% · MXCT: -1.44%
6M Horizon MXCT +25.26 pp
BVS: +6.47% · MXCT: +31.73%
1Y Horizon BVS +66.43 pp
BVS: +47.02% · MXCT: -19.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BVS Revenue MXCT Revenue BVS Op. Margin MXCT Op. Margin Margin Leader
FY2019 $340M $10M 9.2% -93.7% BVS
FY2020 $320M $20M 6.6% -71.6% BVS
FY2021 $430M $20M 2.8% -84.3% BVS
FY2022 $510M $30M -32.7% -95.2% BVS
FY2023 $510M $20M -16.0% -247.7% BVS
FY2024 $570M $20M -2.7% -230.5% BVS
FY2025 $570M $20M 9.5% -247.6% BVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BVS BREAKDOWN
76d in phase · OBV DISTRIBUTION
Current IV 448.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BVS Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $681.3M market capitalization and 10.1% operating margin.
OpEx & R&D Reinvestment 58.6% of Rev ($343M)
90D Engineering Disclosures 0 Published
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BVS vs MXCT Key Questions & Quantitative Answers

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BVS carries a Unified Composite Score of 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin). Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. MXCT 41.7/100 SELL) and 0.85β · 74% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BVS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BVS leads the Growth & Scale pillar: BVS posts +2.7% YoY revenue growth and +69.7% YoY earnings growth on $586M TTM revenue (68.7% gross margin, 10.1% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), BVS cumulative revenue shifted +67.6% while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, BVS deploys 58.6% of Rev ($343M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.

BVS screens cheaper on headline valuation multiples. BVS trades at 11.1x Forward P/E, 12.3x Trailing P/E, 1.20x PEG, and 1.5x EV/Revenue (14.5% FCF margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BVS (25.8% ROE) versus MXCT (-16.9% ROE) capital efficiency.

In options market volatility and institutional positioning, BVS carries 448.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 74% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.